| US 7,534,887 B2 | ||
| Thiazoline derivative and use of the same | ||
| Keiji Kubo, Osaka (Japan); Takanobu Kuroita, Osaka (Japan); Masaki Kawamura, Osaka (Japan); and Hiroki Sakamoto, Osaka (Japan) | ||
| Assigned to Takeda Pharmaceutical Company Limited, Osaka (Japan) | ||
| Appl. No. 10/574,048 PCT Filed Sep. 29, 2004, PCT No. PCT/JP2004/014685 § 371(c)(1), (2), (4) Date May 12, 2006, PCT Pub. No. WO2005/030740, PCT Pub. Date Apr. 07, 2005. |
||
| Claims priority of application No. 2003-341430 (JP), filed on Sep. 30, 2003. | ||
| Prior Publication US 2007/0010528 A1, Jan. 11, 2007 | ||
| Int. Cl. C07D 413/00 (2006.01); A61K 31/497 (2006.01) | ||
| U.S. Cl. 544—369 [514/252.12] | 11 Claims |
1. A compound represented by Formula (I):
 wherein R is naphthyl which may be substituted; X is a bond; X′ is a bond ; Y is a C1-3 alkylene which may be substituted; Y′ is —C(═O)—; ring A is a piperazine ring which may be substituted; Z1 and -Z2 are each a bond; -Z3 is C1-3 alkylene which may be substituted; B is a group represented by the formula:
 (wherein R1, R3 and R4 are each a hydrogen atom or a C1-6 alkyl which may be substituted, and R3 and R4 may be bonded to each other to form tetrahydroimidazole which may be substituted); and a is 0, 1 or 2,
or a salt thereof.
|